Study Design and Methodology
Study Population
Inclusion Criteria
Key Exclusion Criteria
Study Outcomes
Study Limitations
Adapted with permission from SAGE Publications, Inc.
TECFIDERA reduced the risk of relapse at 2 years vs placebo
*ARR was calculated using a negative binomial regression model adjusted for baseline EDSS score (≤2.0 vs >2.0), baseline age (<40 vs ≥40 years), study, region, and number of relapses in the 1 year prior to DEFINE/CONFIRM study entry.
Adapted with permission from SAGE Publications, Inc.
93% of newly diagnosed patients taking TECFIDERA remained free of disability progression at 2 years compared with 77% taking placebo
†Estimated proportion of patients with disability progression at week 96 was derived using Kaplan-Meier analysis. HR, 95% CI, and P value were based on a stratified Cox proportional hazards model with study as the stratifying variable, adjusted for baseline EDSS score (as a continuous variable), baseline age (<40 vs ≥40), and region.